NeuroPace Q2 revenue $10.2M (-19% YoY); net loss $12.7M; signs exclusive DIXI Medical SEEG distribution deal

NeuroPace Inc

2022-Q2 EPS reported -$0.99 revenue$21,574,000

Q2 total revenue $10.2M vs $12.6M YoY; initial implant revenue $8.0M, replacement $2.2M.
Net loss $12.7M vs $8.5M YoY; operating expenses $18.4M up from $14.0M.
FY 2022 guidance: total revenue $43-45M, initial implant $34-36M; DIXI Medical revenue ~$1.5M in Q4.
Signed exclusive 3-year U.S. distribution deal for DIXI Medical SEEG electrodes; total payments of $4.5M.
Cash and equivalents $92.4M, down from $103.2M at March 31; long-term borrowings $51.0M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.